Pharming Group N.V. (PHGN.F)
Frankfurt · EUR · Healthcare · Biotechnology
€1.04 (+4.19%) as of
Key statistics
- Market cap
- 738.57M
- P/E (TTM)
- 104.35
- Forward P/E
- -34.78
- EPS (TTM)
- 0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.8194 – 1.7620
- Beta
- 0.07
- Revenue (TTM)
- 366.48M
- Profit margin
- 2.54%
- Volume
- 275.00
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Leiden, Netherlands
- Employees
- 407
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.